Gelesis Holdings, Inc. – NYSE:GLS
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Gelesis Holdings stock price monthly change
-92.43%
month
Gelesis Holdings stock price quarterly change
-95.78%
quarter
Gelesis Holdings stock price yearly change
-99.76%
year
Gelesis Holdings key metrics
Market Cap | 11.63M |
Enterprise value | 89.77K |
P/E | -0.12 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | -0.44 |
PEG ratio | N/A |
EPS | -0.69 |
Revenue | 12.14M |
EBITDA | -52.47M |
Income | -50.39M |
Revenue Q/Q | -87.66% |
Revenue Y/Y | -37.74% |
Profit margin | -581.33% |
Oper. margin | -572.78% |
Gross margin | 34.68% |
EBIT margin | -572.78% |
EBITDA margin | -432.27% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGelesis Holdings stock price history
Gelesis Holdings stock forecast
Gelesis Holdings financial statements
| Sep 2022 | 6.65M | -14.14M | -212.7% |
|---|---|---|---|
| Dec 2022 | 2.62M | -23.41M | -890.98% |
| Mar 2023 | 1.75M | -5.14M | -293.55% |
| Jun 2023 | 1.10M | -7.68M | -693.86% |
| Sep 2022 | 130517000 | 123.63M | 94.73% |
|---|---|---|---|
| Dec 2022 | 103324000 | 115.79M | 112.06% |
| Mar 2023 | 98780000 | 112.57M | 113.96% |
| Jun 2023 | 95875000 | 114.5M | 119.43% |
| Sep 2022 | -21.68M | -3.40M | 24.81M |
|---|---|---|---|
| Dec 2022 | -16.27M | -647K | -681K |
| Mar 2023 | -8.69M | -224K | 4.59M |
| Jun 2023 | -3.23M | 0 | 0 |
Gelesis Holdings alternative data
| Aug 2023 | 93 |
|---|---|
| Sep 2023 | 93 |
| Oct 2023 | 93 |
| Nov 2023 | 93 |
| Dec 2023 | 93 |
| Jan 2024 | 93 |
| Feb 2024 | 93 |
| Mar 2024 | 93 |
| Apr 2024 | 93 |
| May 2024 | 93 |
| Jun 2024 | 93 |
| Jul 2024 | 93 |
Gelesis Holdings other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2022 | 100000 | 0 |
| May 2023 | 266129542 | 0 |
| Jun 2023 | 0 | 0 |
| Sep 2023 | 0 | 0 |
| Quarter | Transcript |
|---|---|
| Q3 2022 14 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 15 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 14 May 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 24 Mar 2022 | Q4 2021 Earnings Call Transcript |
-
When is Gelesis Holdings's next earnings date?
Unfortunately, Gelesis Holdings's (GLS) next earnings date is currently unknown.
-
Does Gelesis Holdings pay dividends?
No, Gelesis Holdings does not pay dividends.
-
How much money does Gelesis Holdings make?
Gelesis Holdings has a market capitalization of 11.63M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 130.37% to 25.77M US dollars.
-
What is Gelesis Holdings's stock symbol?
Gelesis Holdings, Inc. is traded on the NYSE under the ticker symbol "GLS".
-
What is Gelesis Holdings's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Gelesis Holdings?
Shares of Gelesis Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Gelesis Holdings have?
As Jul 2024, Gelesis Holdings employs 93 workers.
-
When Gelesis Holdings went public?
Gelesis Holdings, Inc. is publicly traded company for more then 3 years since IPO on 14 Jan 2022.
-
What is Gelesis Holdings's official website?
The official website for Gelesis Holdings is gelesis.com.
-
Where are Gelesis Holdings's headquarters?
Gelesis Holdings is headquartered at 501 Boylston Street, Boston, MA.
-
How can i contact Gelesis Holdings?
Gelesis Holdings's mailing address is 501 Boylston Street, Boston, MA and company can be reached via phone at +61 74564718.
Gelesis Holdings company profile:
Gelesis Holdings, Inc.
gelesis.comExchange:
NYSE
Full time employees:
93
Industry:
Biotechnology
Sector:
Healthcare
Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.
501 Boylston Street
Boston, MA 02116
Boston, MA 02116
CIK: 0001805087
:
CUSIP: 36850R204
